Please use this identifier to cite or link to this item:
https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/1086
Title: | Association between serum lithium level and incidence of COVID-19 infection |
Authors: | Geddes, John R |
Keywords: | COVID-19 Lithium |
Issue Date: | Mar-2022 |
Citation: | De Picker, L., Leboyer, M., Geddes, J., Morrens, M., Harrison, P., & Taquet, M. (2022). Association between serum lithium level and incidence of COVID-19 infection. The British Journal of Psychiatry, 221(1), 425-427 |
Abstract: | An antiviral effect of lithium has been proposed, but never investigated for coronavirus disease 2019 (COVID-19). Using electronic health records of 26 554 patients with documented serum lithium levels during the pandemic, we show that the 6-month COVID-19 infection incidence was lower among matched patients with ‘therapeutic’ (0.50–1.00) versus ‘subtherapeutic’ (0.05–0.50) lithium levels (hazard ratio (HR) = 0.82, 95% CI 0.69–0.97, P = 0.017) and among patients with ‘therapeutic’ lithium levels versus matched patients using valproate (HR = 0.79, 95% CI 0.67–0.92, P = 0.0023). Lower rates of infection were observed for both new COVID-19 diagnoses and positive polymerase chain reaction tests, regardless of underlying psychiatric diagnosis and vaccination status. |
Description: | Available with an NHS OpenAthens log in for eligible users |
URI: | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/1086 |
Appears in Collections: | Population Health |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.